Table 3. → indicates “followed by”; mPR,... | American Society of Hematology

Table 3.

Phase 3 trials evaluating novel agent-based continuous therapy for transplant-ineligible patients

Phase 3 trials evaluating novel agent-based continuous therapy for transplant-ineligible patients

→ indicates “followed by”; mPR, low-dose MPR; R, lenalidomide; and T, thalidomide.

This Feature Is Available To Subscribers Only

Sign In or Create an Account